Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2020 | Daratumumab in the management of AL amyloidosis

Morie Gertz • 23 Sep 2020
ISA 2020
Amyloidosis Rare Diseases Antibodies Bortezomib Cyclophosphamide Daratumumab Dexamethasone Isatuximab Ixazomib Lenalidomide Melphalan

Daratumumab may be a promising treatment for newly-diagnosed patients with light chain (AL) amyloidosis. Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, discusses the drug treatment options in AL amyloidosis, specifically focussing on the role of daratumumab. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Morie Gertz

1:36
Results from VITAL: survival benefit of birtamimab in Mayo Stage IV AL amyloidosis
Morie Gertz • 21 Nov 2022
1:33
The role of allogeneic transplantation in patients with multiple myeloma
Morie Gertz • 21 Nov 2022
1:34
The importance of identifying AH amyloidosis in patients with normal free light chain levels
Morie Gertz • 21 Nov 2022
1:37
MRD as a prognostic tool but not for clinical decision-making in multiple myeloma
Morie Gertz • 21 Nov 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals